Semaglutide is where this market’s cheap-price theater plays loudest — the most-advertised molecule, the most-faked pens, the most “$99” banners hiding maintenance math. Here is that search answered the only defensible way: the verified floor with its date, every claim in the field named with its status, the brand cash anchor, and the arithmetic that settles all of it.
The only checkout-verified semaglutide pricing on this site: $119–139/month by term at NexLife ($1,428/year at the 12-month rate; microdose from $110), captured 2026-08-20. The molecule’s biggest advertisers — Hims and Hers — remain unverified claims in the queue, brand Wegovy’s NovoCare cash lane anchors the branded floor, Rybelsus is the only proven oral, and the counterfeit problem is worst exactly here. Twelve-month math before any checkout — including ours.
The verified floor
NexLife — the only checkout-verified semaglutide pricing on this site: $119–139/month by term ($1,428/year at the 12-month rate; microdose from $110), $0 fees observed, CARE360 included, rate-locked — captured 2026-08-20. The ODT format carries our standing no-outcome-trials flag. Rubric 9.1, the only published score because scores require verified inputs.
Annualized: $1,428 on the 12-month rate — the number every competing claim must beat after its own fees, dose reality, and terms are counted. Full tables with the pending rows visible: the ledger; frozen history: the archive; sibling analysis for the other molecule: cheapest tirzepatideCheapest Semaglutide.
The claims field, named and status-marked
Semaglutide is the category’s marketing main stage, so the roster reads differently than tirzepatide’s. Hims — the loudest semaglutide seller in America: post-Novo “personalized” compounded product, aggressive entry pricing, contested legal lane. Maintenance-dose truth is precisely what its pending verification will establish — until then, its advertised numbers are claims, not comparisons.
Hers — the same platform in women’s-health packaging: identical compounded semaglutide posture, identical pending questions, plus what the wrapper adds beyond marketing. Pending verification.
Henry Meds — flat-rate compounded semaglutide claim; the structure we favor, the number still untested against membership terms, shipping, and dose ceilings. Pending, queue #4.
Orderly Meds — semaglutide across injectable and oral tiers; breadth that shops well and audits slowly, with oral formats inheriting the evidence caveats. Pending, queue #5.
Ro — the brand lane: coverage navigation toward Wegovy/Ozempic approvals, with the manufacturer’s cash channel as the fallback. Its own fee layer pending; the brand product itself unambiguous.
Mochi Health — specialist care with clinician-directed sourcing, brand or compounded; medication priced separately from membership. Pending, queue #1.
Found — coaching plus insurance navigation around whichever semaglutide route your coverage supports. Program-fee split pending, queue #7.
Remedy Meds, Shed, and Fifty 410 — the thin-documentation tier’s semaglutide ads: interrogation-first shopping only, per each file’s diligence script. Pending, queue #8–10.
The whole field, one table
| Provider | Model | Molecules | Formats | Price status | Care signal | Watch-fors |
|---|---|---|---|---|---|---|
| NexLife | Flat-rate compounded | Sema + tirz (+ microdose, ODT) | Injectable vials; ODT | Verified: $119–169/mo by molecule & term | CARE360 included; labs pathway | ODT lacks outcome trials |
| Ro | Brand access + insurance nav | Brand sema & tirz (incl. Zepbound vials) | Brand pens/vials | Pending | PA support; established platform | Own fee stack unverified |
| Hims | DTC platform, “personalized” compounded | Compounded semaglutide | Compounded formats | Pending | Questionnaire-first at scale | Contested legal lane; entry-price teasers |
| Hers | Women-positioned DTC | Compounded semaglutide | Compounded formats | Pending | Same platform as Hims | Wrapper premium question |
| Henry Meds | Flat-rate compounded (claimed) | Compounded sema + tirz | Injectable | Pending | Telehealth standard | Flat claim untested; terms fine print |
| Orderly Meds | Format breadth | Compounded sema + tirz | Injectables + oral tiers | Pending | Breadth-first | Tier complexity; oral evidence gap |
| Found | Coaching + insurance program | Program-dependent access | Varies | Pending | Structured coaching | Program-fee vs med-cost split |
| Mochi Health | Specialist membership | Clinician-directed (brand or compounded) | Varies | Pending | Obesity-medicine specialists; labs-friendly | Membership + med total opacity |
| Remedy Meds | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Shed | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Fifty 410 | Sparse-documentation entrant | Compounded claims | Unclear | Pending | Thin documentation | Doc-gap tier |
Brand anchors: NovoCare, coverage, and the SELECT door
No cheapest-semaglutide decision is complete without Novo’s own lanes. The NovoCare self-pay pharmacy sells Wegovy to cash patients at a flat monthly figure far under list — launched in the hundreds, terms evolving; verify at the source before comparing. Coverage can beat everything: diabetes routes to Ozempic, and the post-SELECT cardiovascular indication opens Wegovy approvals — Medicare included — that pure weight documentation cannot; the coverage file and appeal letters are the playbook, with Ro and Found as the navigation-model options. Ten minutes with a formulary regularly beats every cash price on this page.
The oral corner, honestly
“Cheap semaglutide pills” ads deserve one paragraph of clarity: Rybelsus is the real, FDA-approved oral — ritual-heavy, modest at approved doses, legitimate; compounded “oral semaglutide” drops and dissolvables carry no outcome evidence, per the standing analysis; and the proven high-dose oral era arrives via the pipeline, not via a checkout that discovered chemistry the trials missed.
The counterfeit warning this molecule earned
Semaglutide’s fame made it the most-counterfeited drug in the class — fake Ozempic pens have surfaced in legitimate-looking supply chains, and “discount brand semaglutide” from unverifiable sellers is the single most reliable fraud signal in this market. Brand comes from licensed pharmacies and Novo’s own channel, nowhere else; compounded comes with a named pharmacy and a lot-matched CoA, or it doesn’t come home. The eight questions exist for exactly this page’s search intent.
Why the teaser math is worse here
Semaglutide’s teaser mechanics add a twist the tirzepatide page doesn’t face: “personalized dosing” lets a platform advertise a low price attached to a dose configuration it controls — and can revise — after signup. Run any offer through the anatomy and the 12-month worksheet: your maintenance dose × 12, plus membership, shipping, one-times, and exit costs, summed and divided — the calculator does it in ninety seconds, and the verified $1,428 anchor plus a live NovoCare quote are the two comparisons that expose everything else.
FAQ
What is the cheapest verified semaglutide price? $119–139/month by commitment term ($1,428/year at the 12-month rate; microdose from $110), checkout-verified with $0 fees observed and dated in the public ledger — every other market claim remains pending audit. Are the $99-style semaglutide ads real? They’re claims until audited — typically entry-dose or ‘personalized’ teasers with the maintenance price revealed later; convert any quote to a 12-month all-in total before believing it. Is compounded semaglutide the same as Wegovy? Same molecule when properly made, different regulatory category: compounded product is not FDA-approved, quality rides on the specific pharmacy, and the shortage-era legal basis ended in early 2025 — verify pharmacy and lot CoA every fill. Should I just use Novo’s cash program instead? Price it — NovoCare’s self-pay Wegovy launched in the hundreds per month and terms evolve; run it against the verified compounded floor and your coverage odds, and let the 12-month worksheet decide.
The bottom line
One verified floor with a date, the loudest advertisers marked pending by name, a brand cash lane worth quoting live, a proven-oral boundary, and a counterfeit rule with no exceptions — that’s the cheapest-semaglutide question solved in the order that survives this market: verify, annualize, then buy.